0000899243-16-015092.txt : 20160302 0000899243-16-015092.hdr.sgml : 20160302 20160302210212 ACCESSION NUMBER: 0000899243-16-015092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160229 FILED AS OF DATE: 20160302 DATE AS OF CHANGE: 20160302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2066960703 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bishop Hans Edgar CENTRAL INDEX KEY: 0001480212 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 161479334 MAIL ADDRESS: STREET 1: 60 WEST 66TH STREET, 26A CITY: NEW YORK STATE: NY ZIP: 10023 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-02-29 0 0001594864 Juno Therapeutics, Inc. JUNO 0001480212 Bishop Hans Edgar C/O 307 WESTLAKE AVENUE NORTH, SUITE 300 SEATTLE WA 98109 1 1 0 0 See Remarks Common Stock 2016-02-29 4 M 0 54000 6.36 A 2741359 D Common Stock 2016-02-29 4 S 0 86871 35.2659 D 2654488 D Common Stock 2016-02-29 4 S 0 3879 36.4582 D 2650609 D Stock Option (right to buy) 6.36 2016-02-29 4 M 0 54000 0.00 D 2024-09-08 Common Stock 54000 893506 D 1/48 of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter. This transaction was executed in multiple trades at prices ranging from $34.78 to $35.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $35.90 to $36.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2014, as amended March 20, 2015. Chief Executive Officer and President /s/ Zachary Hale, attorney-in-fact 2016-03-02